This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart

Macy's Inc (NYSE:M) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors.

Since February 2021, Macy’s stock’s one-year return has outperformed several of the world’s most popular vaccine stocks: Moderna Inc (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), BioNTech SE - ADR (NASDAQ:BNTX), Novavax, Inc. (NASDAQ:NVAX) and Vaxart Inc (NASDAQ:VXRT).

Founded in 1858, Macy's operates nearly 600 stores as the Macy's brand, 58 stores as the Bloomingdale's brand and 160 freestanding Bluemercury specialty beauty stores.

Macy's also operates e-commerce sites, owns 65% of a Chinese e-commerce joint venture, and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances make up a majority of Macy’s sales. 

Here's how the returns break down from February 2021 to present: 

• Novavax is down from $273.98 to $86.55 for a return of -68.41%
• Vaxart is down from $7.94 to $5.04 for a return of -36.52%
• Moderna is down from $176.76 to $151.81 for a return of -14.12%
• Pfizer is up from $34.89 to $49.68 for a return of 42.39%
• BioNTech is up from $113.56 to $165.49 for a return of 45.73%
• And finally, Macy’s is up from $14.70 to $26.11 for a return of 77.62%.